ADC Development for Urothelial Tumor

With seven approved antibody-drug conjugates (ADCs) and over 50 others in clinical development, significant advances have been made in recent years to bring ADC technology to the forefront of drug development. Creative Biolabs has  extraordinary rich experience in generating ADCs specific for different targets involved in diverse cancers such as Lymphoma, Breast Cancer, Lung cancer, Gliomas, and urothelial cancer. We offer a comprehensive set of anti-urothelial tumor ADC development services for our global clients.

Introduction of Urothelial Tumor

Urothelial tumor, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer that starts in the urothelial cells, which line the inside of the bladder and other parts of the urinary tract. Urothelial cancer is thought to involve the entire urothelium as a multifocal field change. It may arise at any location along the course of the urothelium between the urethra and the renal pelvis. Locally advanced or metastatic urothelial cancer is an aggressive form of cancer with high recurrence rates and low survival. The major causes of urothelial cancer include the duration and amount of cigarette smoking and other tobacco use, occupational exposure to chemicals, chronic irritation of the lining of the bladder, parasitic infections. Tests and procedures used to diagnose bladder cancer may include cystoscopy, biopsy, urine cytology, imaging tests. Treatments for urothelial cancer mainly include: surgery, chemotherapy, radiation therapy, and immunotherapy.

Main liquid biopsies in urothelial carcinoma of the bladder and upper urinary tract carcinoma. Fig.1 Main liquid biopsies in urothelial carcinoma of the bladder and upper urinary tract carcinoma. (Miyake, 2018)

ADC Therapy for Urothelial Tumor

In the past years, significant progress has been made in understanding the biology of the urothelial tumor and the development of immunotherapies and targeted therapies. Several biomarkers involved in urothelial tumor have been identified and some were regarded as potential targets to develop ADCs. For instance, SLITRK6 is a membrane protein with low levels of expression in normal tissues, but high levels of expression in certain types of cancer including urothelial tumor, making it an ideal target for an antibody-drug therapeutic agent. An antibody targeting the SLITRK6 antigen has been linked with a cytotoxic agent monomethyl auristatin E (AGS15E) and is currently in phase I clinical trials for patients with metastatic urothelial carcinoma. Besides, Sacituzumab govitecan (IMMU-132) is an ADC targeting TROP2 and delivering SN-38. Multiple early-phase clinical trials have demonstrated safety and clinical benefit of IMMU-132 across urothelial cancer. Besides, TROP2-targeted therapy in combination with other targeted therapy has also been applied.

ADC Development for Urothelial Tumor

What Can We Do for You?

Creative Biolabs focuses on developing ADCs for the treatment of hematological cancers and solid tumors. We can help our clients develop noval ADCs that are highly targeted biopharmaceutical products, combining monoclonal antibodies (mAbs) specific to tumor antigens with a novel class of highly potent warheads via a appropriate linker. With a deep understanding of ADCs and the oncology treatment landscape, scientists from Creative Biolabs are dedicated to efficiently progressing potential best-in-class ADCs to address significant unmet scientific and preclinical needs. We now offer the following ADC development services, please refer to the corresponding section for more information.

If the target you are interested in is not included, please contact us directly for a customized service. We are more than happy to share our experience with you.


  1. Miyake, M.; et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Research and reports in urology. 2018, 10: 251.

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us